EI
STOK icon

EAM Investors’s Stoke Therapeutics STOK Stock Holding History

EAM Investors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,000
Closed -$1.69M – 373
2026
Q1 		$1.69M Sell
52,000
-65,823
-56% -$2.16M 0.2% 176
2025
Q4 		$3.74M Sell
117,823
-2,358
-2% -$70.9K 0.42% 127
2025
Q3 		$2.78M Buy
+120,181
New +$2.06M 0.32% 145
2024
Q4 		– Sell
-30,781
Closed -$378K – 349
2024
Q3 		$378K Sell
30,781
-6,856
-18% -$97.1K 0.06% 237
2024
Q2 		$508K Sell
37,637
-8,208
-18% -$111K 0.08% 229
2024
Q1 		$619K Buy
+45,845
New +$278K 0.1% 226

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's STOK Position: Q2 2026 in Review

EAM Investors sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 52,000 shares — an estimated $1.69M sold.

EAM Investors first reported a position in STOK in Q1 2024 and held it in 6 quarters. The position peaked at $3.74M in Q4 2025. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • EAM Investors reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 52,000 Stoke Therapeutics shares in Q2 2026, an estimated $1.69M.
  • EAM Investors first reported a position in Stoke Therapeutics in Q1 2024 and held it in 6 quarters.
  • EAM Investors's Stoke Therapeutics position peaked at $3.74M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.